Internal Medicine, Medical Oncology · Palm Beach Gardens, FL
NPI
1407852585
Since 2005
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
3401 Pga Blvd Ste 200
Palm Beach Gardens, FL, 33410
Phone (561) 366-4100
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.8M
97,982 services
Medicare patients, 2024
1,302
Average age 76
Drug cost, 2024
$3.0M
1,872 prescriptions
Company payments, 2025
$3,468
From 32 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Elisabeth A McKeen was code J0897 (injection, denosumab, 1 mg), 8,760 times for 72 patients. In total Elisabeth A McKeen billed 97,982 services in 141 codes, and Medicare paid $1.8M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-08-11.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0897 Injection, denosumab, 1 mg | Office | 8,760 | 72 | $20.38 | $179K |
| Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | Office | 4,260 | 52 | $0.10 | $427 |
| J9395 Injection, fulvestrant, 25 mg | Office | 4,060 | 33 | $6.26 | $25K |
| 85025 Blood Count | Office | 2,157 | 1,055 | $7.61 | $16K |
| 36415 Venipuncture Blood Collection | Office | 1,865 | 968 | $8.65 | $16K |
| 99214 Office E&M - Established | Office | 1,301 | 721 | $95.44 | $124K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 1,266 | 30 | $0.09 | $113 |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 1,130 | 22 | $0.73 | $824 |
| 99213 Office E&M - Established | Office | 787 | 642 | $65.27 | $51K |
| 96372 Injection Administration | Office | 486 | 139 | $10.55 | $5,127 |
| 96402 Chemotherapy Administration | Office | 400 | 34 | $26.24 | $10K |
| J3420 Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | Office | 299 | 48 | $0.94 | $281 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 231 | 172 | $12.88 | $2,976 |
| 96375 Injection Administration | Office | 225 | 29 | $11.96 | $2,691 |
| 96367 Intravenous Infusion, Hydration | Office | 167 | 20 | $22.00 | $3,675 |
By year: 2022 $1.8M for 106,947 services; 2023 $1.8M for 106,532 services; 2024 $1.8M for 97,982 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 2,157 | 1,055 | $7.61 | $16K |
| 36415 Venipuncture Blood Collection | 1,865 | 968 | $8.65 | $16K |
| 81003 Clinical Chemistry | 26 | 19 | $2.12 | $55.13 |
| 85046 Blood Count | 16 | 16 | $5.18 | $82.83 |
Medicare prescription drug claims, 2024
In 2024, the drug Elisabeth A McKeen prescribed most often to Medicare patients was Letrozole, with 494 prescriptions and refills. In total Elisabeth A McKeen wrote 1,872 Medicare prescriptions that cost $3.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Letrozole Generic | 494 | 1,345 | 152 | $12K |
| Anastrozole Generic | 371 | 973 | 109 | $6,643 |
| Lorazepam Generic | 95 | 99 | 32 | $437 |
| Ibrance Palbociclib | 84 | 91 | 14 | $1.4M |
| Exemestane Generic | 78 | 191 | 27 | $20K |
| Alprazolam Generic | 57 | 61 | 21 | $337 |
| Tamoxifen Citrate Generic | 57 | 139 | 17 | $1,658 |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | 41 | 41 | 12 | $1,958 |
| Zolpidem Tartrate Generic | 31 | 51 | Under 11 | $385 |
| Kisqali Ribociclib Succinate | 29 | 29 | Under 11 | $404K |
| Orserdu Elacestrant Hcl | 29 | 29 | Under 11 | $673K |
| Ondansetron Hcl Generic | 26 | 26 | 18 | $185 |
| Escitalopram Oxalate Generic | 24 | 73 | Under 11 | $340 |
| Dexamethasone Generic | 21 | 21 | Under 11 | $401 |
| Truqap Capivasertib | 21 | 21 | Under 11 | $398K |
Brand drugs: 246 claims; generic drugs: 1,626 claims; opioid claims: 59.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Elisabeth A McKeen $3,468 ($3,468 in general payments such as food, travel and fees) from 32 companies. The largest payer was Novartis Pharmaceuticals Corporation with $1,358.
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation NVS | 46 | $1,358 |
| Daiichi Sankyo Inc. 4568.T | 13 | $283 |
| Abbvie Inc. ABBV | 9 | $170 |
| Celgene Corporation BMY | 13 | $167 |
| GlaxoSmithKline, LLC. GSK | 12 | $160 |
| Pfizer Inc. PFE | 17 | $151 |
| Genentech USA, Inc. ROG.SW | 5 | $133 |
| Merck Sharp & Dohme LLC MRK | 5 | $122 |
| Janssen Biotech, Inc. JNJ | 4 | $108 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 3 | $84.65 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.